ABEONA THERAPEUTICS INC. (ABEO): Results of Operations and Financial Condition
ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau
How this was made
The 30-second read
Why it matters
Key trading-relevant items are (1) Q2 revenue growth and patient-treatment counts, (2) CMS NTAP status effective Oct 1, 2026, and (3) cash balance decline plus revenue recognition variability tied to manufacturing yield/lot release.
Market read
The filing provides fresh, decision-relevant catalysts for ABEO: NTAP reimbursement pathway timing, expanding QTC footprint, and updated financial and cash metrics.
What to watch
Cash fell materially in the quarter ($191.4M to $146.8M), so investors may focus on runway and whether QTC expansion translates into sustained, fully recognized revenue.
Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million
ZEVASKYN revenue and treatment activity advanced, while revenue-recognition and manufacturing-yield issues persisted, net loss widened sequentially, and cash, cash equivalents and short-term investments declined from December 31, 2025.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, netGAAP | $ 11,380 | 31% | – |
| License and other revenuesGAAP | — | – | – |
| Total revenuesGAAP | 11,380 | – | – |
| Cost of salesGAAP | 4,177 | – | – |
| RoyaltiesGAAP | — | – | – |
| Research and developmentGAAP | 5,021 | – | – |
| Selling, general and administrativeGAAP | 15,835 | – | – |
| Total costs and expensesGAAP | 25,033 | – | – |
| Loss from operationsGAAP | (13,653) | – | – |
| Interest incomeGAAP | 1,355 | – | – |
| Interest expenseGAAP | (696) | – | – |
| Change in fair value of warrant liabilitiesGAAP | (7,191) | – | – |
| Gain from sale of priority review voucher, netGAAP | — | – | – |
| Other (loss) income, netGAAP | (6) | – | – |
| Income (loss) before income taxesGAAP | (20,191) | – | – |
| Income tax expenseGAAP | — | – | – |
| Net (loss) incomeGAAP | $ (20,191) | – | – |
| Basic (loss) income per common shareGAAP | $ (0.35) | – | – |
| Dilutive (loss) income per common shareGAAP | $ (0.35) | – | – |
| Weighted average number of common shares outstanding, basicGAAP | 57,048,385 | – | – |
| Weighted average number of common shares outstanding, dilutiveGAAP | 57,048,385 | – | – |
| Six-month product revenue, netGAAP | $ 20,100 | – | – |
| Six-month license and other revenuesGAAP | — | – | – |
| Six-month total revenuesGAAP | 20,100 | – | – |
| Six-month cost of salesGAAP | 6,873 | – | – |
| Six-month royaltiesGAAP | — | – | – |
| Six-month research and developmentGAAP | 14,576 | – | – |
| Six-month selling, general and administrativeGAAP | 35,337 | – | – |
| Six-month total costs and expensesGAAP | 56,786 | – | – |
| Six-month loss from operationsGAAP | (36,686) | – | – |
| Six-month interest incomeGAAP | 2,709 | – | – |
| Six-month interest expenseGAAP | (1,526) | – | – |
| Six-month change in fair value of warrant liabilitiesGAAP | (1,805) | – | – |
| Six-month gain from sale of priority review voucher, netGAAP | — | – | – |
| Six-month other income, netGAAP | 44 | – | – |
| Six-month income (loss) before income taxesGAAP | (37,264) | – | – |
| Six-month income tax expenseGAAP | 2 | – | – |
| Six-month net (loss) incomeGAAP | $ (37,266) | – | – |
| Six-month basic (loss) income per common shareGAAP | $ (0.66) | – | – |
| Six-month dilutive (loss) income per common shareGAAP | $ (0.66) | – | – |
| Six-month weighted average number of common shares outstanding, basicGAAP | 56,835,833 | – | – |
| Six-month weighted average number of common shares outstanding, dilutiveGAAP | 56,835,833 | – | – |
What drove it
- Five patients were treated with ZEVASKYN during the second quarter of 2026, with revenue recognized for four treatments.
- Three patients have completed treatments in the third quarter of 2026 to-date, and 12 patient treatments have been completed since launch.
- NewYork-Presbyterian/Columbia University Irving Medical Center and Children’s Hospital of Philadelphia were activated as QTCs during the second quarter of 2026.
- CHOP and University of Texas Medical Branch have commenced collection of patient biopsies, and CHOP has treated its first patient with ZEVASKYN.
- Cincinnati Children’s was activated as a ZEVASKYN QTC in the third quarter of 2026.
- Selling, general and administrative expenses decreased primarily due to fewer engineering runs and less manufacturing training costs in the second quarter of 2026.
- Research and development expenses in the first quarter of 2026 included the one-time, up-front cost of $7.0 million for in-licensing ABO-701.
Concerns
- Revenue was not recognized for two patients due to low manufacturing yield or not meeting lot release specifications.
- One batch yielded fewer than the threshold number of sheets for revenue recognition during the second quarter of 2026.
- Net loss was $(20.2) million in the second quarter of 2026, compared to $(17.1) million in the first quarter of 2026.
- The change in fair value of warrant liabilities was $(7,191) for the three months ended June 30, 2026.
- Cash, cash equivalents and short-term investments were $146.8 million as of June 30, 2026, compared to $191.4 million as of December 31, 2025.
What to watch
- Treatment completions and revenue recognition as the growing number of QTCs progress patients through the treatment process.
- Manufacturing yield and the ability to produce ZEVASKYN batches that meet product release specifications.
- The October 1, 2026 effective date for CMS New Technology Add-On Payment status for ZEVASKYN.
- Hospital adoption and access for Medicare patients, who represent approximately 10 percent of RDEB patients.
- Further QTC activations, patient biopsy collections, and patient treatments.
Balance sheet and cash flow
- Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, compared to $191.4 million as of December 31, 2025.
- Total assets: $ 179,507 as of June 30, 2026; $ 219,570 as of December 31, 2025.
- Total liabilities: $ 51,449 as of June 30, 2026; $ 60,354 as of December 31, 2025.
- Total stockholders’ equity: $ 128,058 as of June 30, 2026; $ 159,216 as of December 31, 2025.
- Common stock outstanding: 57,225,919 as of June 30, 2026; 55,043,413 as of December 31, 2025.
- Common stock and common stock equivalents: 71,098,537 as of June 30, 2026; 69,103,212 as of December 31, 2025.
- Common stock warrants (pre-funded): 4,933,489 as of June 30, 2026; 5,113,321 as of December 31, 2025.
- Common stock and pre-funded warrants: 62,159,408 as of June 30, 2026; 60,156,734 as of December 31, 2025.
- Options to purchase common stock: 168,670 as of June 30, 2026; 176,019 as of December 31, 2025.
- Conversion option to redeem common stock: 614,251 as of June 30, 2026; 614,251 as of December 31, 2025.
- Warrants to purchase common stock: 8,156,208 as of June 30, 2026; 8,156,208 as of December 31, 2025.
Analysis
Abeona reported $11.4 million of net ZEVASKYN revenue in the second quarter of 2026, up 31% quarter-over-quarter from $8.7 million in the first quarter of 2026. Five patients were treated in the quarter and revenue was recognized for four treatments. Treatment activity continued into the third quarter, with three treatments completed to date, bringing completed treatments since launch to 12.
The revenue result also highlights commercial and manufacturing execution constraints. Revenue was not recognized for two patients due to low manufacturing yield or not meeting lot release specifications. In the second quarter, one batch yielded fewer than the threshold number of sheets required for revenue recognition. These issues make the relationship between patient treatments and recognized revenue a central operating measure.
Operating expenses moved lower sequentially in the reported expense categories discussed by the company. R&D expense was $5.0 million versus $9.6 million in the first quarter, which had included a one-time, up-front cost of $7.0 million for in-licensing ABO-701. SG&A was $15.8 million versus $19.5 million, primarily reflecting fewer engineering runs and less manufacturing training costs. Despite these reductions, net loss was $(20.2) million, compared with $(17.1) million in the first quarter, and the quarter included a $(7,191) change in fair value of warrant liabilities.
Commercial infrastructure expanded during and after the quarter. NewYork-Presbyterian/Columbia University Irving Medical Center and CHOP were activated in the second quarter, while Cincinnati Children’s was activated in the third quarter. CHOP and UTMB commenced patient-biopsy collections, and CHOP treated its first patient. CMS NTAP status becomes effective October 1, 2026 and is expected by the company to support hospital adoption and Medicare patient access.
Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, compared with $191.4 million as of December 31, 2025. The filing provided no quantitative financial guidance, operating cash flow, free cash flow, gross-margin disclosure, debt balance, repurchase activity, or dividend activity. Investor attention is therefore centered on treatment throughput, recognized revenue per completed treatment, manufacturing consistency, QTC patient onboarding, and the effect of NTAP status on access and hospital adoption.
Management, verbatim
Our confidence in ZEVASKYN’s substantial opportunity is reinforced by our launch progress and experience to date as we engage with a growing number of patients and expand our QTC network.
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
As early real-world experience with ZEVASKYN matures across activated sites, we expect to drive broader adoption and long-term growth.
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
Not in the filing
stated, not guessed- Forward financial guidance
- Prior-quarter total revenue
- Gross profit and gross margin
- Non-GAAP financial measures
- Operating cash flow
- Free cash flow
- Debt balance
- Share repurchases
- Dividends
- Reportable segment revenue disclosure
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and a commercial update for ZEVASKYN (prademagene zamikeracel).
Ticker impact
Abeona reported Q2 2026 ZEVASKYN revenue of $11.4M (+31% QoQ) and disclosed CMS NTAP approval effective Oct 1, 2026.
Moderate positive bias for ABEO as NTAP can support Medicare access and hospital adoption, partially offset by ongoing cash decline and yield-related revenue timing.
The filing is a primary disclosure (8-K with results and business update) including a concrete CMS payment pathway effective Oct 1, 2026, plus operational KPIs (patients treated, QTC activations). However, revenue recognition variability (two patients not recognized) and cash decline from $191.4M to $146.8M reduce certainty on near-term fundamentals.
Market effects
Reinforces the commercial and reimbursement pathway importance for rare-disease cell and gene therapies, potentially supporting sentiment toward similar commercial-stage programs.
Limited direct regional impact; Cleveland manufacturing and US hospital network expansion are the main operational links.
Primarily US reimbursement-driven; limited immediate global read-through beyond rare-disease payer dynamics.
Counterpoint
NTAP is supportive, but the company’s revenue recognition is still constrained by manufacturing yield and lot release specifications, so adoption gains may lag.
Key entities
- issuerAbeona Therapeutics Inc.
Commercial-stage biopharmaceutical company reporting Q2 2026 results and ZEVASKYN business update.
- productZEVASKYN (prademagene zamikeracel)
Autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).
- regulator/payerCenters for Medicare & Medicaid Services (CMS)
Granted NTAP status under the FY2027 Hospital Inpatient Prospective Payment System Final Rule effective Oct 1, 2026.
